Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Aardvark Therapeutics (NASDAQ:AARD), a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic diseases, has granted inducement stock options to two new employees. The awards, issued on August 28, 2025, consist of options to purchase 20,013 shares of common stock at an exercise price of $8.49 per share.
The options were granted under the company's 2025 Inducement Equity Incentive Plan and will vest over four years, with 25% vesting after one year and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment.
Aardvark Therapeutics (NASDAQ:AARD), società biofarmaceutica in fase clinica che sviluppa terapie a piccola molecola per le malattie metaboliche, ha assegnato opzioni azionarie di incentivo a due nuovi dipendenti. Le assegnazioni, con data del 28 agosto 2025, prevedono il diritto di acquistare 20.013 azioni ordinarie a un prezzo di esercizio di $8,49 per azione.
Le opzioni sono state concesse ai sensi del piano di incentivazione azionaria 2025 dell'azienda e matureranno in quattro anni: il 25% dopo il primo anno e il restante verrà maturato mensilmente a ritmo di 1/48 del totale, subordinato alla permanenza in servizio.
Aardvark Therapeutics (NASDAQ:AARD), una compañía biofarmacéutica en fase clínica que desarrolla terapias pequeñas para enfermedades metabólicas, ha otorgado opciones sobre acciones como incentivo a dos nuevos empleados. Las adjudicaciones, fechadas el 28 de agosto de 2025, permiten comprar 20.013 acciones ordinarias a un precio de ejercicio de $8,49 por acción.
Las opciones se concedieron bajo el Plan de Incentivos de Capital 2025 de la compañía y devengarán en cuatro años: el 25% tras el primer año y el resto se devengará mensualmente a razón de 1/48 del total, condicionado a la continuidad en el empleo.
Aardvark Therapeutics (NASDAQ:AARD), 대사 질환용 저분자 치료제를 개발하는 임상 단계의 생명공학 기업이 두 명의 신규 직원에게 유인 주식매수선택권을 부여했습니다. 해당 수여는 2025년 8월 28일자로 이루어졌으며, 보통주 20,013주를 주당 $8.49의 행사가로 매수할 수 있는 권리입니다.
이 옵션은 회사의 2025년 유인형 지분 인센티브 플랜에 따라 부여되었으며 4년간 베스팅됩니다: 1년 후 25%가 베스트되고 나머지는 총 주식의 1/48씩 매월 베스트되며 계속 근무해야 합니다.
Aardvark Therapeutics (NASDAQ:AARD), une société biopharmaceutique en phase clinique développant des petites molécules pour les maladies métaboliques, a attribué des options d'achat d'actions incitatives à deux nouveaux employés. Les attributions, datées du 28 août 2025, portent sur la possibilité d'acheter 20 013 actions ordinaires au prix d'exercice de 8,49 $ par action.
Les options ont été accordées dans le cadre du Plan d'incitation en actions 2025 de la société et acquerront droit sur quatre ans : 25% après un an, le solde étant acquis mensuellement à raison de 1/48 du total, sous réserve de la poursuite de l'emploi.
Aardvark Therapeutics (NASDAQ:AARD), ein klinisch tätiges Biopharmaunternehmen, das kleinmolekulare Therapeutika für Stoffwechselerkrankungen entwickelt, hat zwei neuen Mitarbeitern Incentive-Aktienoptionen gewährt. Die Zuteilungen, datiert auf den 28. August 2025, berechtigen zum Erwerb von 20.013 Aktien des Stammkapitals zu einem Ausübungspreis von $8,49 je Aktie.
Die Optionen wurden im Rahmen des Equity-Incentive-Plans 2025 des Unternehmens gewährt und vesten über vier Jahre: 25% nach einem Jahr, der Rest vests monatlich in Höhe von 1/48 der Gesamtanzahl, vorausgesetzt, das Arbeitsverhältnis besteht fort.
- None.
- None.
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that on August 28, 2025, two new employees were granted inducement awards consisting of stock options to purchase an aggregate of 20,013 shares of common stock.
Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan, and was granted as an inducement material to each employee’s employment with Aardvark in accordance with Nasdaq Listing Rule 5635(c)(4).
The exercise price of each option is equal to the closing price of Aardvark’s common stock on the date of grant, or
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food). Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. ARD-101 is also being studied in hypothalamic obesity. Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions. For more information, visit aardvarktherapeutics.com.
Contact:
Carolyn Hawley, Inizio Evoke Comms
(619) 849-5382
Carolyn.hawley@inizioevoke.com
FAQ
What stock options did Aardvark Therapeutics (AARD) grant to new employees in August 2025?
What is the vesting schedule for Aardvark Therapeutics' (AARD) inducement stock options?
What is Aardvark Therapeutics' (AARD) main business focus?
Under which plan were the Aardvark Therapeutics (AARD) inducement awards granted?
